Viridian slips on pricing $270M stock offering

Aug. 17, 2022 6:30 AM ETViridian Therapeutics, Inc. (VRDN)By: Preeti Singh, SA News Editor
  • Viridian Therapeutics (NASDAQ:VRDN) shares dropped 3% pre-market on Wednesday after the biotechnology company priced an upsized underwritten public offering of common stock and preferred stock.
  • The offering comprises ~9.63M shares of common stock, issued at $23.50/share, and 28,084 shares of series B preferred stock issued at $1,566.745/share, which are convertible into ~1.87M shares of common stock.
  • In addition, Viridian (VRDN) has granted the underwriters a 30-day option to purchase an additional 1,725,000 shares of common stock at the public offering price.
  • Gross proceeds are estimated to be $270M; net proceeds will be used to support the company's clinical development programs, as well as for working capital and general corporate purposes.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.